WO2005005661A3 - Genes regulated in ovarian cancer as prognostic and therapeutic targets - Google Patents

Genes regulated in ovarian cancer as prognostic and therapeutic targets Download PDF

Info

Publication number
WO2005005661A3
WO2005005661A3 PCT/EP2004/007167 EP2004007167W WO2005005661A3 WO 2005005661 A3 WO2005005661 A3 WO 2005005661A3 EP 2004007167 W EP2004007167 W EP 2004007167W WO 2005005661 A3 WO2005005661 A3 WO 2005005661A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
prognostic
therapeutic targets
genes regulated
patient
Prior art date
Application number
PCT/EP2004/007167
Other languages
French (fr)
Other versions
WO2005005661A2 (en
Inventor
Christian Nicolas Lavedan
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Christian Nicolas Lavedan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Christian Nicolas Lavedan filed Critical Novartis Ag
Priority to US10/562,406 priority Critical patent/US20060281091A1/en
Priority to EP04740533A priority patent/EP1644522A2/en
Priority to MXPA05014220A priority patent/MXPA05014220A/en
Priority to CA002531091A priority patent/CA2531091A1/en
Priority to AU2004256182A priority patent/AU2004256182A1/en
Priority to BRPI0412110-4A priority patent/BRPI0412110A/en
Priority to JP2006518084A priority patent/JP2007526749A/en
Publication of WO2005005661A2 publication Critical patent/WO2005005661A2/en
Publication of WO2005005661A3 publication Critical patent/WO2005005661A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to the use of genomic analysis to detect the presence of ovarian cancer in a patient from a sample of tissue or blood and to kits for carrying out this determination. In addition this invention relates to methods to treat a patient with ovarian cancer.
PCT/EP2004/007167 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as prognostic and therapeutic targets WO2005005661A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/562,406 US20060281091A1 (en) 2003-07-07 2004-07-01 Genes regulated in ovarian cancer a s prognostic and therapeutic targets
EP04740533A EP1644522A2 (en) 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as prognostic and therapeutic targets
MXPA05014220A MXPA05014220A (en) 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as prognostic and therapeutic targets.
CA002531091A CA2531091A1 (en) 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as prognostic and therapeutic targets
AU2004256182A AU2004256182A1 (en) 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as prognostic and therapeutic targets
BRPI0412110-4A BRPI0412110A (en) 2003-07-02 2004-07-01 genes regulated in ovarian cancer as prognostic and therapeutic targets
JP2006518084A JP2007526749A (en) 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as a prognostic and therapeutic target

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48446503P 2003-07-02 2003-07-02
US60/484,465 2003-07-02

Publications (2)

Publication Number Publication Date
WO2005005661A2 WO2005005661A2 (en) 2005-01-20
WO2005005661A3 true WO2005005661A3 (en) 2005-07-14

Family

ID=34062046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/007167 WO2005005661A2 (en) 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as prognostic and therapeutic targets

Country Status (8)

Country Link
EP (1) EP1644522A2 (en)
JP (1) JP2007526749A (en)
CN (1) CN1845999A (en)
AU (1) AU2004256182A1 (en)
BR (1) BRPI0412110A (en)
CA (1) CA2531091A1 (en)
MX (1) MXPA05014220A (en)
WO (1) WO2005005661A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100068207A1 (en) * 2005-04-07 2010-03-18 Abdallah Fanidi DDR2 in Cancer Diagnosis, Detection and Treatment
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
CA2669492A1 (en) * 2006-11-13 2008-05-22 Dermagene Oy Methods and uses involving genetic abnormalities at chromosome 12
GB0815846D0 (en) * 2008-09-01 2008-10-08 Immunovia Ab diagnosis, prognosis and imaging of disease
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ607326A (en) * 2010-08-27 2015-01-30 Universitaetsklinikum Muenster Means and methods for the detection of a predisposition of a female subject to recurrent pregnancy loss (rpl), preeclampsia (pe) and/or fetal growth restriction (fgr)
MX369911B (en) 2013-05-30 2019-11-26 Genomic Health Inc Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer.
CN103920150B (en) * 2014-04-17 2016-02-03 北京大学第一医院 The application of SATB1 in treatment cutaneous T cell lymphoma
JP6436477B2 (en) * 2014-05-13 2018-12-12 国立大学法人大阪大学 Pharmaceutical composition for cancer treatment
JP6168625B2 (en) * 2016-01-12 2017-07-26 国立研究開発法人産業技術総合研究所 Epithelial ovarian cancer differentiation marker
CN106841622B (en) * 2017-04-07 2019-01-18 南通大学附属医院 Application of the SCML2 in diagnosis gastro-entero-pancreatic tumor
CN108085392A (en) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 Biomarker of ovarian epithelial carcinoma and application thereof
CN110241198A (en) * 2019-05-30 2019-09-17 成都吉诺迈尔生物科技有限公司 A kind of genome recombination fingerprint and its identification method characterizing hHRD HR defective
CN112229999B (en) * 2020-09-01 2022-04-22 浙江省肿瘤医院 Prognostic diagnosis marker Claudin21 for ovarian cancer and application thereof
CN113684277B (en) * 2021-09-06 2022-05-17 南方医科大学南方医院 Method for predicting ovarian cancer homologous recombination defect based on biomarker of genome copy number variation and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018542A2 (en) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
WO2001070979A2 (en) * 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
US20030003479A1 (en) * 2001-04-19 2003-01-02 Millennium Pharmaceutical, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2003021229A2 (en) * 2001-09-05 2003-03-13 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018542A2 (en) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
WO2001070979A2 (en) * 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
US20030003479A1 (en) * 2001-04-19 2003-01-02 Millennium Pharmaceutical, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2003021229A2 (en) * 2001-09-05 2003-03-13 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
HAVIV IZHAK ET AL: "DNA microarrays for assessing ovarian cancer gene expression", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 191, no. 1, 31 May 2002 (2002-05-31), pages 121 - 126, XP002314762, ISSN: 0303-7207 *
HOUGH C D ET AL: "Coordinately up-regulated genes in ovarian cancer.", CANCER RESEARCH. 15 MAY 2001, vol. 61, no. 10, 15 May 2001 (2001-05-15), pages 3869 - 3876, XP002299703, ISSN: 0008-5472 *
HOUGH C D ET AL: "Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.", CANCER RESEARCH. 15 NOV 2000, vol. 60, no. 22, 15 November 2000 (2000-11-15), pages 6281 - 6287, XP002215320, ISSN: 0008-5472 *
MATEI DANIELA ET AL: "Gene expression in epithelial ovarian carcinoma.", ONCOGENE. 12 SEP 2002, vol. 21, no. 41, 12 September 2002 (2002-09-12), pages 6289 - 6298, XP002314759, ISSN: 0950-9232 *
MORIN PATRICE J: "Functional genomics approaches in cancer research", CURRENT GENOMICS, vol. 3, no. 5, October 2002 (2002-10-01), pages 425 - 436, XP009042923, ISSN: 1389-2029 *
MUGGIA FRANCO ET AL: "Emerging treatments for ovarian cancer.", EXPERT OPINION ON EMERGING DRUGS. MAY 2003, vol. 8, no. 1, May 2003 (2003-05-01), pages 203 - 216, XP009043003, ISSN: 1472-8214 *
ONO KENJI ET AL: "Identification by cDNA microarray of genes involved in ovarian carcinogenesis", CANCER RESEARCH, vol. 60, no. 18, 15 September 2000 (2000-09-15), pages 5007 - 5011, XP002314754, ISSN: 0008-5472 *
PEPE MARGARET SULLIVAN ET AL: "Selecting differentially expressed genes from microarray experiments.", BIOMETRICS, vol. 59, no. 1, March 2003 (2003-03-01), pages 133 - 142, XP008039470, ISSN: 0006-341X *
SAWIRIS G PETER ET AL: "Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.", CANCER RESEARCH. 15 MAY 2002, vol. 62, no. 10, 15 May 2002 (2002-05-15), pages 2923 - 2928, XP002314758, ISSN: 0008-5472 *
SCHUMMER M ET AL: "Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 238, no. 2, 1 October 1999 (1999-10-01), pages 375 - 385, XP002222131, ISSN: 0378-1119 *
SCHWARTZ DONALD R ET AL: "Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.", CANCER RESEARCH. 15 AUG 2002, vol. 62, no. 16, 15 August 2002 (2002-08-15), pages 4722 - 4729, XP002314761, ISSN: 0008-5472 *
SHRIDHAR V ET AL: "Genetic analysis of early- versus late-stage ovarian tumors.", CANCER RESEARCH. 1 AUG 2001, vol. 61, no. 15, 1 August 2001 (2001-08-01), pages 5895 - 5904, XP002314760, ISSN: 0008-5472 *
SMITH DAVID I: "Transcriptional profiling develops molecular signatures for ovarian tumors", CYTOMETRY, vol. 47, no. 1, 1 January 2002 (2002-01-01), pages 60 - 62, XP009042914, ISSN: 0196-4763 *
TAPPER J ET AL: "Changes in gene expression during progression of ovarian carcinoma.", CANCER GENETICS AND CYTOGENETICS. 1 JUL 2001, vol. 128, no. 1, 1 July 2001 (2001-07-01), pages 1 - 6, XP002314757, ISSN: 0165-4608 *
VAN DER ZEE A G ET AL: "Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO. JAN 1994, vol. 5, no. 1, January 1994 (1994-01-01), pages 75 - 81, XP009042999, ISSN: 0923-7534 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *
VIJVER VAN DE M J ET AL: "THE NEW ENGLAND JOURNAL OF MEDICINE A GENE-EXPRESSION SIGNATURE AS A PREDICTOR OF SURVIVAL IN BREAST CANCER", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 347, no. 25, 19 December 2002 (2002-12-19), pages 1999 - 2009, XP008032093, ISSN: 1533-4406 *
WELSH J B ET AL: "Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 3, 30 January 2001 (2001-01-30), pages 1176 - 1181, XP002975970, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2005005661A2 (en) 2005-01-20
JP2007526749A (en) 2007-09-20
BRPI0412110A (en) 2006-11-21
MXPA05014220A (en) 2006-03-09
AU2004256182A1 (en) 2005-01-20
EP1644522A2 (en) 2006-04-12
CN1845999A (en) 2006-10-11
CA2531091A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2005084109A3 (en) Cancer specific gene mh15
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2006008128A3 (en) Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
AU2003253986A1 (en) Gene expression profiling in biopsied tumor tissues
WO2005010486A3 (en) Biomarker panel for colorectal cancer
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2009019368A3 (en) Method for the assay of liver fatty acid-binding protein, ace and ca19-9 for the in vitro diagnosis of colorectal cancer
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2006037462A3 (en) Cancer markers
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
WO2005095651A3 (en) Molecular markers of cisplatin resistance in cancer and uses thereof
WO2002022879A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2005085863A3 (en) Biomarker: compound correlations in cancer diagnosis and therapy
WO2004047514A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480025033.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004256182

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004740533

Country of ref document: EP

Ref document number: PA/a/2005/014220

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2531091

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006518084

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004256182

Country of ref document: AU

Date of ref document: 20040701

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004256182

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004740533

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006281091

Country of ref document: US

Ref document number: 10562406

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0412110

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10562406

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004740533

Country of ref document: EP